Undecimal Bio raises EUR16M seed backed by 4BIO Capital, Entrée Capital, Harel Tech, IQ Capital, Kerna Ventures, Saras Capital, Verve Ventures
The funding round closed on October 1, 2026, with participation from seven investors including 4BIO Capital, Entrée Capital, and Harel Tech among others. Undecimal Bio has not previously recorded any financing rounds on Brouky.
Undecimal Bio operates in the Healthcare & Life Sciences sector, developing siRNA therapeutics using combinatorial chemistry and transformer-based AI. The company is located in the United Kingdom and was co-founded by Yaniv Erlich and Shaul Ilan. It targets renovascular diseases affecting the kidney and vascular system.
Brouky tracks 360 deals in the UK Healthcare & Life Sciences category over the past 12 months, with a median amount of EUR6.9M.
Related insights
- Deal SpotlightUbitium raises EUR14M seed backed by Florian Seibel, Ibex Investors, Inflection Partners, KBC Focus Fund, OpenOcean, Runa Capital
- Deal SpotlightSpiko raises EUR79.9M Series B backed by NEA
- Deal SpotlightSteady Energy raises EUR69.8M Series C+ backed by 3North Partners
- Deal Spotlightإم إن تي - حالا raises EUR38000000 Series B with CIB participating
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.